{
    "clinical_study": {
        "@rank": "100732", 
        "arm_group": [
            {
                "arm_group_label": "phenolic acid + maltodextrin", 
                "arm_group_type": "Experimental", 
                "description": "phenolic acid + maltodextrin;"
            }, 
            {
                "arm_group_label": "Maltodextrin", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Maltodextrin"
            }, 
            {
                "arm_group_label": "flavanol + maltodextrin", 
                "arm_group_type": "Active Comparator", 
                "description": "flavanol + maltodextrin"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective is to demonstrate the effect of phenolic acids on endothelial function."
        }, 
        "brief_title": "Bioefficacy of Phenolic Acids", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Endothelial Dysfunction", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy,  Men and women\n\n          -  Subjects with endothelial dysfunction defined as a basal brachial artery\n             flow-mediated dilatation (FMD) measurement between 3% and 8% at screening\n\n        Exclusion Criteria:\n\n          -  Any food allergy\n\n          -  Abnormal blood pressure defined as follow:  systolic <100 or >160 mmHg and diastolic\n             <50 or >100mmHg\n\n          -  Pregnancy or lactating women\n\n          -  Regular consumption of cholesterol-lowering or antihypertensive medication\n\n          -  Smokers\n\n          -  Inability to restrain from caffeine/tea and alcohol for 12hrs prior to study visits\n             (intake1 day before screening measurements (and 1 day before each visit)\n\n          -  Not restrain the intake of multivitamin-tablets and other supplemental compounds 10\n             days before the study start and throughout the study.\n\n          -  Excessive alcohol intake defined as > 280 g  per week for men and >210g per week for\n             women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "14", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01781559", 
            "org_study_id": "11.35.NRC"
        }, 
        "intervention": {
            "arm_group_label": [
                "phenolic acid + maltodextrin", 
                "Maltodextrin", 
                "flavanol + maltodextrin"
            ], 
            "description": "phenolic acid", 
            "intervention_name": "phenolic acid", 
            "intervention_type": "Dietary Supplement"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "December 11, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Perth", 
                    "country": "Australia", 
                    "zip": "6000"
                }, 
                "name": "School of Medicine and Pharmacology - University of WA"
            }
        }, 
        "location_countries": {
            "country": "Australia"
        }, 
        "number_of_arms": "3", 
        "official_title": "Effect of Phenolic Acids on the Human Vasculature", 
        "overall_official": {
            "affiliation": "School of Medicine and Pharmacology - University of WA", 
            "last_name": "Kevin Croft, Professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Australia: Human Research Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change from predose in percent change of flow-mediated dilatation at 1h compared to control treatment", 
            "safety_issue": "No", 
            "time_frame": "After 1 hour"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01781559"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Change from predose in blood pressure at 0.5h", 
            "safety_issue": "No", 
            "time_frame": "After 30 min"
        }, 
        "source": "Nestl\u00e9", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Nestl\u00e9", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}